ISSN 1662-4009 (online)

ey0015.3-6 | Maternal thyroid disease during pregnancy | ESPEYB15

3.6 Maternal thyroid function and child educational attainment: prospective cohort study

SM Nelson , C Haig , A Mc Connachie , N Sattar , SM Ring , GD Smith , DA Lawlor , RS Lindsay

To read the full abstract: BMJ 2018;360:k452The role of thyroid hormones during early gestation is well established by animal studies. In humans, previous studies have shown that maternal hypothyroxinemia was associated with either an early reduction in psychomotor scales (e.g. Bayley scale of infant development) or later in late infancy or adolescence. However, randomized controlled trials on...

ey0017.3-5 | Follow-up paper - Graves disease | ESPEYB17

3.5. Teprotumumab for the treatment of active thyroid eye disease

RS Douglas , GJ Kahaly , A Patel , S Sile , EHZ Thompson , R Perdok , JC Fleming , BT Fowler , C Marcocci , M Marino , A Antonelli , R Dailey , GJ Harris , A Eckstein , J Schiffman , R Tang , C Nelson , M Salvi , S Wester , JW Sherman , T Vescio , RJ Holt , TJ Smith

To read the full abstract: N Engl J Med. 2020;382:341–352.Teprotumumab, an IGF-1R monoclonal antibody, showed promising results for the treatment of Graves’ orbitopathy in a first phase 2 study reported in 2017 [1]. Here, this randomized double-masked, placebo controlled phase 3 multicenter study confirms those initial promising results in patients with moderate-to severe Graves’ eye disease: The primary outcome of proptosis reduc...